NCT06739252 2026-01-28
Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA
Peking University
Phase 2 Terminated
Peking University
CSPC Ouyi Pharmaceutical Co., Ltd.
Stanford University
University of Utah
Helsinn Healthcare SA